64Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients

EJNMMI Research

Table 2 Accumulation of ⁶⁴ Cu-DOTA-trastuzumab in brain tumor

Patient number	Lesion number	Location	SUVmax (tumor/BG)		TNR
Patient number	Lesion number	Location	24 h	48 h	24 h	48 h
1	1	Rt-cerebellum	1.4/0.2	2.1/0.2	9.3	12.5
	2	Rt-cerebellum	1.3/0.2	2.1/0.2	8.7	12.4
	3	Vermis	1.4/0.2	2.1/0.2	9.1	12.4
	4	Lt-cerebellum	1.1/0.2	1.6/0.2	7.1	11.8
2	5	Lt-cerebellum	1.2/0.1	2.1/0.2	8.2	12.2
3	6	Lt-frontal	0.7/0.2	1.0/0.2	4.1	5.5
	7	Lt-frontal	0.6/0.2	0.7/0.2	3.3	4.1
4	8	Lt-frontal	0.9/0.2	1.6/0.2	5.8	9.2
	9	Rt-cerebellum	0.8/0.2	1.2/0.2	5.1	7.8
5	10	Lt-cerebellum	1.1/0.2	NA/NA	6.1	NA

⁶⁴Cu-DOTA-trastuzumab PET imaging at 48 h after injection was not carried out because of surgical resection.
BG, background; NA, inpatient no. 5.